If you've searched how to get retatrutide in Australia this year, you've probably noticed the answer keeps shifting overseas while staying still here. August 2026 was a good example: Eli Lilly confirmed on 3 August that a defined group of patients can now apply for early access to retatrutide before FDA approval — a pathway the company built after weeks of pressure from doctors. It's a real change in how the drug reaches people. It just isn't a change to anything an Australian GP can write on a script pad.

Here's what actually happened, and what it does and doesn't mean at this end of the world.

How an access pathway got built out of one patient

The trigger, as reported by STAT, was unusual. A well-connected patient obtained compassionate-use access to retatrutide outside the trial programme. Once other doctors learned of it, they asked Lilly for the same option for their own patients. On 3 August 2026 the company agreed, and opened applications to a defined patient group.

Two things are worth holding onto there. First, expanded access of this kind is a company-run programme with eligibility criteria set by the sponsor and the relevant regulator — not a general release, and not a supply channel. Second, the reporting describes a US-centred process: physician pushback aimed at a US company ahead of a US filing. None of the coverage I can find describes an Australian arm, and I'm not going to guess at one.

Lilly has said it plans to submit a biologics licence application for retatrutide to the FDA in the first quarter of 2027. That's the FDA, not the TGA. Our regulator works from its own dossier, on its own clock — see /clinical-trials for where the evidence package currently sits.

How to get retatrutide in Australia right now

Plainly: retatrutide is investigational in Australia. It is not TGA-approved for weight loss or anything else, so there is no approved product, no PBS listing, and no ordinary prescription pathway. Eli Lilly has indicated it plans to begin regulatory filings from 2027, which means any Australian decision sits behind that.

The routes that exist for an unapproved medicine anywhere are narrow by design: enrolment in a clinical trial, or a sponsor-run access programme where one exists and the patient meets its criteria. Both are gated by the sponsor and the regulator, not by demand. More on the Australian picture at /australia.

For most people reading this, that leaves the current generation of approved options — semaglutide (Ozempic, Wegovy: one receptor) and tirzepatide (Mounjaro, Zepbound: two receptors) — as the things a doctor can actually discuss today. Retatrutide's difference is the third receptor, glucagon, which is why the trial numbers look different. A background explainer is at /what-is-retatrutide.

Why the interest here is so intense

Roughly 66.8% of Australian adults are overweight or obese, and the phase 3 TRIUMPH-1 result — average body weight loss of up to about 28.3% at 12mg over 80 weeks, with 45.3% of participants losing 30% or more — is the largest figure most people have seen attached to an injectable. Lilly also announced on 23 July 2026 that retatrutide succeeded in two further phase 3 obesity trials, though as with much of this programme the first word came via press release rather than a published paper. Treat headline numbers from company announcements as provisional until the full data appear in peer review.

Access interest also has a side effect worth noting: on 12 August 2026, Lilly said it had filed suit against six companies selling versions of its experimental drug, describing it as the start of a broader effort. That's a corporate and legal story rather than a clinical one, but it tells you how far ahead of approval the demand has run.

What the tolerability picture looks like

Across the trials reported to date, the most common adverse events were diarrhoea, nausea, constipation and decreased appetite — the gastrointestinal pattern familiar from the incretin class, generally tied to dose escalation. That's a summary of reported trial data, not a safety profile signed off by any regulator, because no regulator has yet reviewed and approved this drug. Our fuller notes are at /safety.

Watching the Australian clock

There is no TGA submission for retatrutide to point at today. The next verifiable milestone in the public record is Lilly's stated intention to file with the FDA in Q1 2027. If you'd rather not refresh news sites, we'll email when something concrete changes — join the free updates list.

FAQ

How can I get retatrutide in Australia in 2026?

You can't get it through a normal prescription — retatrutide is investigational and not TGA-approved, so there's no approved product or PBS listing. The only legitimate routes for an unapproved medicine are a clinical trial, or a sponsor-run access programme where one exists and you meet its criteria.

Is Eli Lilly's new early access programme open to Australians?

Lilly confirmed on 3 August 2026 that a defined group of patients can apply for early access ahead of FDA approval, following pressure from doctors. The reporting describes a US-focused process ahead of a US filing and does not describe an Australian arm.

When will retatrutide be approved in Australia?

There's no announced TGA submission date. Lilly has said it plans to file a biologics licence application with the FDA in the first quarter of 2027, and has indicated Australian filings would follow from 2027 — approval timing after that is up to the TGA.

What can my doctor prescribe instead while I wait?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are approved medicines in Australia with their own indications and access rules. Whether either is appropriate is a conversation for your GP or a specialist, not something to decide from trial headlines.

Sources

Disclaimer: This article is general information, not medical advice. Retatrutide is an investigational drug that is not approved by the TGA, and nothing here should be used to make treatment decisions — speak with your GP or a qualified health professional. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly.